MAM
BIO icon

Martingale Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Martingale Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-864
Closed -$447K – 888
2020
Q3 		$447K Sell
864
-125
-13% -$63.3K 0.01% 839
2020
Q2 		$448K Hold
989
– – 0.01% 896
2020
Q1 		$348K Sell
989
-300
-23% -$110K ﹤0.01% 866
2019
Q4 		$478K Hold
1,289
– – ﹤0.01% 872
2019
Q3 		$429K Hold
1,289
– – ﹤0.01% 898
2019
Q2 		$404K Hold
1,289
– – ﹤0.01% 919
2019
Q1 		$395K Hold
1,289
– – ﹤0.01% 914
2018
Q4 		$300K Buy
+1,289
New +$346K ﹤0.01% 917
2017
Q1 		– Sell
-2,058
Closed -$376K – 936
2016
Q4 		$376K Sell
2,058
-68,934
-97% -$11.8M 0.01% 868
2016
Q3 		$11.6M Sell
70,992
-27,995
-28% -$4.25M 0.17% 163
2016
Q2 		$14.2M Buy
98,987
+2,895
+3% +$413K 0.23% 142
2016
Q1 		$13.1M Buy
96,092
+19,551
+26% +$2.57M 0.26% 138
2015
Q4 		$10.6M Buy
76,541
+6,500
+9% +$901K 0.24% 156
2015
Q3 		$9.41M Buy
70,041
+22,301
+47% +$3.21M 0.23% 148
2015
Q2 		$7.19M Buy
47,740
+610
+1% +$87.3K 0.17% 184
2015
Q1 		$6.37M Sell
47,130
-22,798
-33% -$2.83M 0.15% 203
2014
Q4 		$8.43M Buy
69,928
+55,720
+392% +$6.41M 0.23% 135
2014
Q3 		$1.61M Buy
14,208
+2,310
+19% +$274K 0.05% 343
2014
Q2 		$1.43M Buy
11,898
+2,100
+21% +$256K 0.04% 396
2014
Q1 		$1.26M Buy
9,798
+1
+0% +$128 0.04% 412
2013
Q4 		$1.21M Buy
9,797
+2,100
+27% +$256K 0.04% 463
2013
Q3 		$905K Sell
7,697
-2,002
-21% -$236K 0.03% 557
2013
Q2 		$1.09M Buy
+9,699
New +$1.14M 0.04% 447

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Martingale Asset Management's BIO Position: Q4 2020 in Review

Martingale Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 864 shares — an estimated $447K sold.

Martingale Asset Management first reported a position in BIO in Q2 2013 and held it in 23 quarters. The position peaked at $14.2M in Q2 2016. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Martingale Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
  • Martingale Asset Management sold 864 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $447K.
  • Martingale Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 23 quarters.
  • Martingale Asset Management's Bio-Rad Laboratories Class A position peaked at $14.2M in Q2 2016.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.